Cargando…
Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
The current guideline treatment for patients with diabetes and nephropathy to lower the high risk of renal and cardiovascular (CV) morbidity and mortality is based on results of clinical studies that have tested new drugs in large groups of patients with diabetes and high renal/CV risk. Although thi...
Autores principales: | de Zeeuw, Dick, Heerspink, Hiddo J L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066539/ https://www.ncbi.nlm.nih.gov/pubmed/32162661 http://dx.doi.org/10.1093/ndt/gfaa013 |
Ejemplares similares
-
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018) -
Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016) -
Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018) -
Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013) -
The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)